Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Recombinant protein based therapeutics for IPF.

Parker JM, Kramer MS, Murray LA.

Inflamm Allergy Drug Targets. 2013 Apr;12(2):109-23. Review.

PMID:
23517648
[PubMed - indexed for MEDLINE]
2.

Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis.

García-Sancho C, Buendía-Roldán I, Fernández-Plata MR, Navarro C, Pérez-Padilla R, Vargas MH, Loyd JE, Selman M.

Respir Med. 2011 Dec;105(12):1902-7. doi: 10.1016/j.rmed.2011.08.022. Epub 2011 Sep 13.

PMID:
21917441
[PubMed - indexed for MEDLINE]
Free Article
3.

Pulmonary fibrosis.

Zisman DA, Keane MP, Belperio JA, Strieter RM, Lynch JP 3rd.

Methods Mol Med. 2005;117:3-44. Review.

PMID:
16130230
[PubMed - indexed for MEDLINE]
4.

Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Borchers AT, Chang C, Keen CL, Gershwin ME.

Clin Rev Allergy Immunol. 2011 Apr;40(2):117-34. doi: 10.1007/s12016-010-8211-5. Review.

PMID:
20838937
[PubMed - indexed for MEDLINE]
5.

Molecular mechanisms in progressive idiopathic pulmonary fibrosis.

Steele MP, Schwartz DA.

Annu Rev Med. 2013;64:265-76. doi: 10.1146/annurev-med-042711-142004. Epub 2012 Sep 27. Review.

PMID:
23020878
[PubMed - indexed for MEDLINE]
6.

Treating IPF--all or nothing? A PRO-CON debate.

Behr J, Kolb M, Cox G.

Respirology. 2009 Nov;14(8):1072-81. doi: 10.1111/j.1440-1843.2009.01645.x. Review.

PMID:
19909457
[PubMed - indexed for MEDLINE]
7.

Emerging evidence for endoplasmic reticulum stress in the pathogenesis of idiopathic pulmonary fibrosis.

Tanjore H, Blackwell TS, Lawson WE.

Am J Physiol Lung Cell Mol Physiol. 2012 Apr 15;302(8):L721-9. doi: 10.1152/ajplung.00410.2011. Epub 2012 Jan 27. Review.

PMID:
22287606
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Current and novel drug therapies for idiopathic pulmonary fibrosis.

Adamali HI, Maher TM.

Drug Des Devel Ther. 2012;6:261-72. doi: 10.2147/DDDT.S29928. Epub 2012 Sep 26. Review.

PMID:
23055696
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Curcumin inhibits fibrosis-related effects in IPF fibroblasts and in mice following bleomycin-induced lung injury.

Smith MR, Gangireddy SR, Narala VR, Hogaboam CM, Standiford TJ, Christensen PJ, Kondapi AK, Reddy RC.

Am J Physiol Lung Cell Mol Physiol. 2010 May;298(5):L616-25. doi: 10.1152/ajplung.00002.2009. Epub 2010 Jan 8.

PMID:
20061443
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

The role of infection in the pathogenesis of idiopathic pulmonary fibrosis.

Molyneaux PL, Maher TM.

Eur Respir Rev. 2013 Sep 1;22(129):376-81. doi: 10.1183/09059180.00000713. Review.

PMID:
23997064
[PubMed - indexed for MEDLINE]
Free Article
11.

Cytokine-like factor 1 gene expression is enriched in idiopathic pulmonary fibrosis and drives the accumulation of CD4+ T cells in murine lungs: evidence for an antifibrotic role in bleomycin injury.

Kass DJ, Yu G, Loh KS, Savir A, Borczuk A, Kahloon R, Juan-Guardela B, Deiuliis G, Tedrow J, Choi J, Richards T, Kaminski N, Greenberg SM.

Am J Pathol. 2012 May;180(5):1963-78. doi: 10.1016/j.ajpath.2012.01.010. Epub 2012 Mar 16.

PMID:
22429962
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy.

Thannickal VJ, Flaherty KR, Martinez FJ, Lynch JP 3rd.

Expert Opin Pharmacother. 2004 Aug;5(8):1671-86. Review.

PMID:
15264982
[PubMed - indexed for MEDLINE]
13.

Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis.

Kim TH, Lee YH, Kim KH, Lee SH, Cha JY, Shin EK, Jung S, Jang AS, Park SW, Uh ST, Kim YH, Park JS, Sin HG, Youm W, Koh ES, Cho SY, Paik YK, Rhim TY, Park CS.

Am J Respir Crit Care Med. 2010 Sep 1;182(5):633-42. doi: 10.1164/rccm.200905-0659OC. Epub 2010 May 12.

PMID:
20463180
[PubMed - indexed for MEDLINE]
14.

Pulmonary hypertension in idiopathic pulmonary fibrosis: a review.

Corte TJ, Wort SJ, Wells AU.

Sarcoidosis Vasc Diffuse Lung Dis. 2009 Jul;26(1):7-19. Review.

PMID:
19960783
[PubMed - indexed for MEDLINE]
15.

Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis.

Hilberg O, Simonsen U, du Bois R, Bendstrup E.

Clin Respir J. 2012 Jul;6(3):131-43. doi: 10.1111/j.1752-699X.2012.00302.x. Review.

PMID:
22697264
[PubMed - indexed for MEDLINE]
16.

Management of idiopathic pulmonary fibrosis.

Cerri S, Spagnolo P, Luppi F, Richeldi L.

Clin Chest Med. 2012 Mar;33(1):85-94. doi: 10.1016/j.ccm.2011.11.005. Epub 2011 Dec 28. Review.

PMID:
22365248
[PubMed - indexed for MEDLINE]
17.

Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case-control study.

García-Sancho Figueroa MC, Carrillo G, Pérez-Padilla R, Fernández-Plata MR, Buendía-Roldán I, Vargas MH, Selman M.

Respir Med. 2010 Feb;104(2):305-9. doi: 10.1016/j.rmed.2009.08.013. Epub 2009 Sep 25.

PMID:
19782552
[PubMed - indexed for MEDLINE]
Free Article
18.

Pirfenidone treatment of idiopathic pulmonary fibrosis.

Azuma A.

Ther Adv Respir Dis. 2012 Apr;6(2):107-14. doi: 10.1177/1753465812436663. Epub 2012 Feb 14. Review.

PMID:
22333982
[PubMed - indexed for MEDLINE]
19.

Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Egypt: a multicenter case-control study.

Awadalla NJ, Hegazy A, Elmetwally RA, Wahby I.

Int J Occup Environ Med. 2012 Jul;3(3):107-16.

PMID:
23022860
[PubMed - indexed for MEDLINE]
Free Article
20.

Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?

de Lauretis A, Veeraraghavan S, Renzoni E.

Chron Respir Dis. 2011;8(1):53-82. doi: 10.1177/1479972310393758. Review.

PMID:
21339375
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk